Schedule 13D ownership disclosure

Tvardi Therapeutics Inc

Common Stock, par value $0.001 per share · CUSIP: 140755307

Event date: 2025-04-15

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Vifor (International) Ltd.Reported CIK 0001675217

    Shares: 205,465 · Class: 2.2%

  • CSL Limited

    Shares: 205,465 · Class: 2.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-054743
Form type
SCHEDULE 13D/A
Filer
Tvardi Therapeutics, Inc.
CIK
CIK 1346830
Filed
Apr 16, 2025
Reporting period
Apr 15, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub